Anticancer activity of stabilized palifosfamide in vivo: Schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin

Anti-Cancer Drugs

Volumn 23, Issue 2, 2012, Pages 173-184

  Jones, Barry ^a   Komarnitsky, Philip ^a   Miller, Glenn T ^a   Amedio, John ^a   Wallner, Barbara P ^a  

^a Ziopharm Oncology Inc   (United States)

Author keywords

alkylating; antineoplastic agents; antineoplastic combined chemotherapy regimens; ifosfamide analogs derivatives

Indexed keywords

ACROLEIN; CHLOROACETALDEHYDE; DOCETAXEL; DOXORUBICIN; IFOSFAMIDE; LYSINE; PALIFOSFAMIDE; PRODRUG; TROMETAMOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FATALITY; DRUG MEGADOSE; DRUG OVERDOSE; FEMALE; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; SOFT TISSUE METASTASIS; SOFT TISSUE SARCOMA; SPRAGUE DAWLEY RAT; TUMOR GROWTH; TUMOR REGRESSION; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL AVAILABILITY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; IFOSFAMIDE; INJECTIONS, INTRAVENOUS; LEUKEMIA, EXPERIMENTAL; LYSINE; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; PHOSPHORAMIDE MUSTARDS; RATS; RATS, SPRAGUE-DAWLEY; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84855214329     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834d73a6     Document Type: Article

References (43)

1. Zhang J, Tian Q, Zhou S-F. Clinical pharmacology of cyclophosphamide and ifosfamide. Curr Drug Therapy 2006; 1:55-84.
2. Struck RF, Dykes DJ, Corbett TH, Suling WJ, Trader MW. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide. Br J Cancer 1983; 47: 15-26. (Pubitemid 13176225)
3. Germann N, Urien S, Rodgers AH, Ratterree M, Struck RF,Waud WR, et al. Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide. Cancer Chemother Pharmacol 2005; 55:143-151. (Pubitemid 40110057)
4. Morgan LR, Struck RF, Rodgers AH, Jursic BS,Waud WR, Papagiannis C, et al. Preclinical pharmacology and toxicology of chemically-stabilized isophosphoramide mustard (ZIO-201) [abstract]. In: Proceedings of the 96th Annual Meeting of the American Association for Cancer Research; 2005; Anaheim, CA. Philadelphia (PA): AACR; 2006. (Abstract no. 4193).
5. Chawla S, Mita M, Verschraegen C, Ryan C, Santoro A, Stevens J, et al. A phase II randomized controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma. In: Proceedings of the 15th Annual Meeting of the Connective Tissue Oncology Society; 5-7 November 2009 Miami, Florida (FL): CTOS; 2009.
6. Verschraegen CF, Chawla SP, Mita MM, Ryan CW, Blakely L, Keedy VL, et al. A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO). J Clin Oncol 2010; 28 (Suppl):7s(Abstract 10004).
7. Brock N, Hilgard P, Peukert M, Pohl J, Sindermann H. Basis and new developments in the field of oxazaphosphorines. Cancer Invest 1988; 6:513-532. (Pubitemid 19042663)
8. Chen CS, Lin JT, Goss KA, He YA, Halpert JR,Waxman DJ. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: Identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol 2004; 65:1278-1285. (Pubitemid 38543498)
9. Rooseboom M, Commandeur JN, Vermeulen NP. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 2004; 56:53-102. (Pubitemid 38314580)
10. Gibson GG, Plant NJ, Swales KE, Ayrton A, El-Sankary W. Receptordependent transcriptional activation of cytochrome P4503A genes: Induction mechanisms, species differences and interindividual variation in man. Xenobiotica 2002; 32:165-206. (Pubitemid 34267348)
11. Boddy AV, Furtun Y, Sardas S, Sardas O, Idle JR. Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide. J Natl Cancer Inst 1992; 84:1744-1748.
12. Chang TK, Yu L, Goldstein JA, Waxman DJ. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 1997; 7:211-221. (Pubitemid 27290635)
13. Brade WP, Herdrich K, Varini M. Ifosfamide -pharmacology, safety and therapeutic potential. Cancer Treat Rev 1985; 12:1-47. (Pubitemid 15021900)
14. Bruggemann SK, Kisro J, Wagner T. Ifosfamide cytotoxicity on human tumor and renal cells: Role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide. Cancer Res 1997; 57:2676-2680. (Pubitemid 27283779)
15. Cerny T, Leyvraz S, von Briel T, Kupfer A, Schaad R, Schmitz SF, et al. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1999; 10: 1087-1094. (Pubitemid 29482464)
16. Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther 1988; 37:301-355.
17. Brock N, Pohl J. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics. IARC Sci Publ 1986;269-279.
18. Woodland C, Ito S, Granvil CP, Wainer IW, Klein J, Koren G. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life Sci 2000; 68:109-117.
19. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103:3684-3688. (Pubitemid 38596282)
20. Schrijvers D, Vermorken JB. Update on the taxoids and other new agents in head and neck cancer therapy. Curr Opin Oncol 1998; 10: 233-241. (Pubitemid 28256929)
21. Spira AI, Ettinger DS. The use of chemotherapy in soft-tissue sarcomas. Oncologist 2002; 7:348-359. (Pubitemid 34919959)
22. Ho PT, Zimmerman K,Wexler LH, Blaney S, Jarosinski P,Weaver-McClure L, et al. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer 1995; 76:2557-2564.
23. Hill DL, Laster WR Jr, Kirk MC, el-Dareer S, Struck RF. Metabolism of iphosphamide (2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3,2- oxazaphosphorine 2-oxide) and production of a toxic iphosphamide metabolite. Cancer Res 1973; 33:1016-1022.
24. Montgomery JA, Struck RF. Synthesis and structure-activity relationships of pre-activated analogs of cyclophosphamide (NSC-26271). Cancer Treat Rep 1976; 60:381-393.
25. Highley MS, Momerency G, Van Cauwenberghe K, Van Oosterom AT, de Bruijn EA, Maes RA, et al. Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans. Drug Metab Dispos 1995; 23:433-437.
26. Komarnitsky P, Amedio J, Schwartz B, Wallner B. ZIO-201 (isophosphoramide mustard, IPM) is an orally active anticancer agent. In: Proceedings of the 98th Annual Meeting of the American Association of Cancer Research; 14-18 April 2007; Los Angeles, CA. Philadelphia (PA): AACR; 2007. (Abstract no. 3200).
27. Komarnitsky P, Amedio J, Wallner B. Oral availability and drug combination activity of ZIO-201 (IPM-tris) in preclinical studies. In: Proceedings of the 99th Annual Meeting of the American Association of Cancer Research; 12-16 April 2008; San Diego, CA. Philadelphia (PA): AACR; 2008. (Abstract no. 5685).
28. Hingorani P, Zhang W, Piperdi S, Pressman L, Lin J, Gorlick R, et al. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. Cancer Chemother Pharmacol 2009; 64:733-740.
29. Benjamin RS, Lo Russo P, Rosen L, Kolb EA, Gorlick RG, Gale RP. Trials of ZIO-201 (isophosphoramide mustard-lysine) (IPM): The active moiety of ifosfamide: Potential role in sarcoma. In: Proceedings of the 12th Annual Meeting of the Connective Tissue Oncology Society; 2-4 November 2006 Venice, Italy: CTOS; 2006.
30. Struck RF, Roychowdhury A, Maddry JA, Waud WR. Development and anti-cancer testing of halogenated analogues of isophosphoramide mustard-lysine (IPM-L; ZIO-201), ZIO-202 and ZIO-203 [Abstract]. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research; 2006 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; 2006. (Abstract no. 548).
31. Emmenegger U, Francia G, Shaked Y, Kerbel RS. Metronomic chemotherapy: Principles and lessons learned from applications in the treatment of metastatic prostate cancer. Recent Results Cancer Res 2010; 180:165-183.
32. Mutsaers AJ. Metronomic chemotherapy. Top Companion Animal Med 2009; 24:137-143.
33. Frederick CA,Williams LD, Ughetto G, van der Marel GA, van Boom JH, Rich A, Wang AH. Structural comparison of anticancer drug-DNA complexes: Adriamycin and daunomycin. Biochemistry 1990; 29: 2538-2549. (Pubitemid 20100850)
34. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 1994; 45:649-656. (Pubitemid 24139191)
35. Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res 1976; 36:2891-2895.
36. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989; 7:126-131. (Pubitemid 19089091)
37. Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verwey J, et al. Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 1987; 23:311-321. (Pubitemid 17033680)
38. Elias AD, Eder JP, Shea T, Begg CB, Frei E III, Antman KH. High-dose ifosfamide with mesna uroprotection: A phase I study. J Clin Oncol 1990; 8:170-178. (Pubitemid 20032461)
39. Frustaci S, De Paoli A, Bidoli E, La Mura N, Berretta M, Buonadonna A, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003; 65 (Suppl 2):80-84. (Pubitemid 37346738)
40. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European organisation for research and treatment of cancer soft tissue and bone sarcoma group study. J Clin Oncol 2007; 25:3144-3150. (Pubitemid 47218064)
41. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M. Ifosfamidebased combination chemotherapy in advanced soft-tissue sarcoma: A practice guideline. Curr Oncol 2007; 14:144-148.
42. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev 2008; 34:339-347.
43. Avendano C, Menendez JC. Medicinal chemistry of anticancer drugs. First edition. Amsterdam: Elsevier; 2008.